Your browser doesn't support javascript.
loading
Constitutional Microsatellite Instability, Genotype, and Phenotype Correlations in Constitutional Mismatch Repair Deficiency.
Gallon, Richard; Phelps, Rachel; Hayes, Christine; Brugieres, Laurence; Guerrini-Rousseau, Léa; Colas, Chrystelle; Muleris, Martine; Ryan, Neil A J; Evans, D Gareth; Grice, Hannah; Jessop, Emily; Kunzemann-Martinez, Annabel; Marshall, Lilla; Schamschula, Esther; Oberhuber, Klaus; Azizi, Amedeo A; Baris Feldman, Hagit; Beilken, Andreas; Brauer, Nina; Brozou, Triantafyllia; Dahan, Karin; Demirsoy, Ugur; Florkin, Benoît; Foulkes, William; Januszkiewicz-Lewandowska, Danuta; Jones, Kristi J; Kratz, Christian P; Lobitz, Stephan; Meade, Julia; Nathrath, Michaela; Pander, Hans-Jürgen; Perne, Claudia; Ragab, Iman; Ripperger, Tim; Rosenbaum, Thorsten; Rueda, Daniel; Sarosiek, Tomasz; Sehested, Astrid; Spier, Isabel; Suerink, Manon; Zimmermann, Stefanie-Yvonne; Zschocke, Johannes; Borthwick, Gillian M; Wimmer, Katharina; Burn, John; Jackson, Michael S; Santibanez-Koref, Mauro.
Afiliação
  • Gallon R; Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK. Electronic address: richard.gallon@newcastle.ac.uk.
  • Phelps R; Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
  • Hayes C; Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
  • Brugieres L; Department of Children and Adolescents Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Guerrini-Rousseau L; Department of Children and Adolescents Oncology, Gustave Roussy, Université Paris-Saclay, Villejuif, France; Team "Genomics and Oncogenesis of pediatric Brain Tumors," INSERM U981, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
  • Colas C; Département de Génétique, Institut Curie, Paris, France; INSERM U830, Université de Paris, Paris, France.
  • Muleris M; Sorbonne Université, Institut National de la Santé et de la Recherche Médicale, Centre de Recherche Saint-Antoine, Paris, France.
  • Ryan NAJ; The Academic Women's Health Unit, Translational Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK; Department of Gynaecology Oncology, Royal Infirmary of Edinburgh, Edinburgh, UK.
  • Evans DG; Division of Evolution, Infection and Genomics, University of Manchester, Manchester, UK.
  • Grice H; Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
  • Jessop E; Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
  • Kunzemann-Martinez A; Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK; Centre for Inflammation and Tissue Repair, University College London, London, UK.
  • Marshall L; Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
  • Schamschula E; Institute of Human Genetics, Medical University of Innsbruck, Innsbruck, Austria.
  • Oberhuber K; Institute of Human Genetics, Medical University of Innsbruck, Innsbruck, Austria.
  • Azizi AA; Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.
  • Baris Feldman H; The Genetics Institute and Genomics Center, Tel Aviv Sourasky Medical Center and Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Beilken A; Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.
  • Brauer N; Pediatric Oncology, Helios-Klinikum, Krefeld, Germany.
  • Brozou T; Department of Pediatric Oncology, Hematology and Clinical Immunology, University Children's Hospital, Medical Faculty, Heinrich Heine University, Duesseldorf, Germany.
  • Dahan K; Centre de Génétique Humaine, Institut de Pathologie et Génétique, Gosselies, Belgium.
  • Demirsoy U; Department of Pediatric Oncology, Kocaeli University, Kocaeli, Turkey.
  • Florkin B; Department of Pediatrics, Citadelle Hospital, University of Liège, Liège, Belgium.
  • Foulkes W; Program in Cancer Genetics, Departments of Oncology and Human Genetics, McGill University, Montreal, Quebec, Canada; Department of Human Genetics, McGill University, Montreal, Quebec, Canada; Department of Medical Genetics, McGill University Health Centre, Montreal, Quebec, Canada; Lady Davis Instit
  • Januszkiewicz-Lewandowska D; Department of Pediatric Oncology, Hematology and Transplantation Medical University, Poznan, Poland.
  • Jones KJ; Department of Clinical Genetics, Western Sydney Genetics Program, Children's Hospital at Westmead, Sydney, New South Wales, Australia; University of Sydney School of Medicine, Sydney, New South Wales, Australia.
  • Kratz CP; Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Germany.
  • Lobitz S; Gemeinschaftsklinikum Mittelrhein, Department of Pediatric Hematology and Oncology, Koblenz, Germany.
  • Meade J; Division of Pediatric Hematology/Oncology, Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
  • Nathrath M; Pediatric Hematology and Oncology, Klinikum Kassel, Kassel, Germany; Department of Pediatrics, Pediatric Oncology Center, Technische Universität München, Munich, Germany.
  • Pander HJ; Institut für Klinische Genetik, Olgahospital, Stuttgart, Germany.
  • Perne C; Institute of Human Genetics, Medical Faculty, University of Bonn and National Center for Hereditary Tumor Syndromes, University Hospital Bonn, Bonn, Germany.
  • Ragab I; Pediatrics Department, Hematology-Oncology Unit, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
  • Ripperger T; Department of Human Genetics, Hannover Medical School, Hannover, Germany.
  • Rosenbaum T; Department of Pediatrics, Sana Kliniken Duisburg, Duisburg, Germany.
  • Rueda D; Hereditary Cancer Laboratory, University Hospital Doce de Octubre, i+12 Research Institute, Madrid, Spain.
  • Sarosiek T; Department of Oncology, Luxmed Onkologia, Warsaw, Poland.
  • Sehested A; Department of Pediatrics and Adolescent Medicine, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Spier I; Institute of Human Genetics, Medical Faculty, University of Bonn and National Center for Hereditary Tumor Syndromes, University Hospital Bonn, Bonn, Germany.
  • Suerink M; Department of Clinical Genetics, Leiden University Medical Center, Leiden, The Netherlands.
  • Zimmermann SY; Department of Pediatric Hematology and Oncology, Children's Hospital, University Hospital, Frankfurt, Germany.
  • Zschocke J; Institute of Human Genetics, Medical University of Innsbruck, Innsbruck, Austria.
  • Borthwick GM; Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
  • Wimmer K; Institute of Human Genetics, Medical University of Innsbruck, Innsbruck, Austria.
  • Burn J; Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
  • Jackson MS; Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
  • Santibanez-Koref M; Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
Gastroenterology ; 164(4): 579-592.e8, 2023 04.
Article em En | MEDLINE | ID: mdl-36586540
ABSTRACT
BACKGROUND &

AIMS:

Constitutional mismatch repair deficiency (CMMRD) is a rare recessive childhood cancer predisposition syndrome caused by germline mismatch repair variants. Constitutional microsatellite instability (cMSI) is a CMMRD diagnostic hallmark and may associate with cancer risk. We quantified cMSI in a large CMMRD patient cohort to explore genotype-phenotype correlations using novel MSI markers selected for instability in blood.

METHODS:

Three CMMRD, 1 Lynch syndrome, and 2 control blood samples were genome sequenced to >120× depth. A pilot cohort of 8 CMMRD and 38 control blood samples and a blinded cohort of 56 CMMRD, 8 suspected CMMRD, 40 Lynch syndrome, and 43 control blood samples were amplicon sequenced to 5000× depth. Sample cMSI score was calculated using a published method comparing microsatellite reference allele frequencies with 80 controls.

RESULTS:

Thirty-two mononucleotide repeats were selected from blood genome and pilot amplicon sequencing data. cMSI scoring using these MSI markers achieved 100% sensitivity (95% CI, 93.6%-100.0%) and specificity (95% CI 97.9%-100.0%), was reproducible, and was superior to an established tumor MSI marker panel. Lower cMSI scores were found in patients with CMMRD with MSH6 deficiency and patients with at least 1 mismatch repair missense variant, and patients with biallelic truncating/copy number variants had higher scores. cMSI score did not correlate with age at first tumor.

CONCLUSIONS:

We present an inexpensive and scalable cMSI assay that enhances CMMRD detection relative to existing methods. cMSI score is associated with mismatch repair genotype but not phenotype, suggesting it is not a useful predictor of cancer risk.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndromes Neoplásicas Hereditárias / Neoplasias Encefálicas / Neoplasias Colorretais / Neoplasias Colorretais Hereditárias sem Polipose Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Gastroenterology Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndromes Neoplásicas Hereditárias / Neoplasias Encefálicas / Neoplasias Colorretais / Neoplasias Colorretais Hereditárias sem Polipose Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Revista: Gastroenterology Ano de publicação: 2023 Tipo de documento: Article